{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:42:35Z","timestamp":1782531755885,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This study evaluated treatment patterns among women diagnosed with symptomatic uterine fibroids (UF) in the United States. Data were retrospectively extracted from the IBM Watson Health MarketScan\u00ae Commercial Claims and Encounters and Medicaid Multi-State databases.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Women aged 18\u201364\u2009years with \u22651 medical claim with a UF diagnosis (primary position, or secondary position plus \u22651 associated symptom) from January 2010 to June 2015 (Commercial) and January 2009 to December 2014 (Medicaid) were eligible; the first UF claim during these time periods was designated the index date. Data collected 12\u2009months pre- and 12 and 60\u2009months post-diagnosis included clinical\/demographic characteristics, pharmacologic\/surgical treatments, and surgical complications. Prevalence (2015) and cumulative incidence (Commercial, 2010\u20132015; Medicaid, 2009\u20132015) of symptomatic UF were estimated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>225,737 (Commercial) and 19,062 (Medicaid) women had a minimum of 12\u2009months post-index continuous enrollment and were eligible for study. Symptomatic UF prevalence and cumulative incidence were: 0.57, 1.23% (Commercial) and 0.46, 0.64% (Medicaid). Initial treatments within 12\u2009months post-diagnosis were surgical (Commercial, 36.7%; Medicaid, 28.7%), pharmacologic (31.7%; 53.0%), or none (31.6%; 18.3%). Pharmacologic treatments were most commonly non-steroidal anti-inflammatory drugs and oral contraceptives; hysterectomy was the most common surgical treatment. Of procedures of abdominal hysterectomy, abdominal myomectomy, uterine artery embolization, and ablation in the first 12\u2009months post-index, 14.9% (Commercial) and 24.9% (Medicaid) resulted in a treatment-associated complication. Abdominal hysterectomy had the highest complication rates (Commercial, 18.5%; Medicaid, 31.0%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Off-label use of pharmacologic therapies and hysterectomy for treatment of symptomatic UF suggests a need for indicated non-invasive treatments for symptomatic UF.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12905-020-01005-6","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T18:04:46Z","timestamp":1597341886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Contemporary treatment utilization among women diagnosed with symptomatic uterine fibroids in the United States"],"prefix":"10.1186","volume":"20","author":[{"given":"Nicole Gidaya","family":"Bonine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vlahiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moore-Schiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/1471-0528.14640","volume":"124","author":"EA Stewart","year":"2017","unstructured":"Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124:1501\u201312.","journal-title":"BJOG."},{"key":"1005_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","volume":"372","author":"EA Stewart","year":"2015","unstructured":"Stewart EA. Uterine fibroids. N Engl J Med. 2015;372:1646\u201355.","journal-title":"N Engl J Med"},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","volume":"2","author":"EA Stewart","year":"2016","unstructured":"Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.","journal-title":"Nat Rev Dis Primers"},{"key":"1005_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejogrb.2010.05.012","volume":"152","author":"E Downes","year":"2010","unstructured":"Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010;152:96\u2013102.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1005_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1185\/03007995.2015.1107534","volume":"32","author":"PY Laberge","year":"2016","unstructured":"Laberge PY, Vilos GA, Vilos AG, Janiszewski PM. Burden of symptomatic uterine fibroids in Canadian women: a cohort study. Curr Med Res Opin. 2016;32:165\u201375.","journal-title":"Curr Med Res Opin"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2014.982246","volume":"31","author":"SS Singh","year":"2015","unstructured":"Singh SS, Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments. Curr Med Res Opin. 2015;31:1\u201312.","journal-title":"Curr Med Res Opin"},{"key":"1005_CR8","volume-title":"Committee Opinion Number 557. Committee on Gynecologic Practice. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women","author":"The American College of Obstetricians and Gynecologists","year":"2013","unstructured":"The American College of Obstetricians and Gynecologists. Committee Opinion Number 557. Committee on Gynecologic Practice. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. 2013. https:\/\/www.acog.org\/-\/media\/Committee-Opinions\/Committee-on-Gynecologic-Practice\/co557.pdf?dmc=1&ts=20180322T1058253663. Accessed 18 Jul 2019."},{"issue":"Suppl 3","key":"1005_CR9","first-page":"S125","volume":"90","author":"The Practice Committee of the American Society for Reproductive Medicine in collaboration with The Society of Reproductive Surgeons","year":"2008","unstructured":"The Practice Committee of the American Society for Reproductive Medicine in collaboration with The Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril. 2008;90(Suppl 3):S125\u201330.","journal-title":"Fertil Steril"},{"key":"1005_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/AOG.0b013e318183fbab","volume":"112","author":"The American College of Obstetricians and Gynecologists","year":"2008","unstructured":"The American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112:387\u2013400.","journal-title":"Obstet Gynecol"},{"key":"1005_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jmig.2008.08.015","volume":"16","author":"CE Miller","year":"2009","unstructured":"Miller CE. Unmet therapeutic needs for uterine myomas. J Minim Invasive Gynecol. 2009;16:11\u201321.","journal-title":"J Minim Invasive Gynecol"},{"key":"1005_CR12","volume-title":"Lupron Depot\u00ae (leuprolide acetate for depot suspension). Prescribing information","author":"AbbVie","year":"2016","unstructured":"AbbVie. Lupron Depot\u00ae (leuprolide acetate for depot suspension). Prescribing information. 2016. http:\/\/www.lupron.com\/prescribing-information.aspx. Accessed 18 Jul 2019."},{"key":"1005_CR13","first-page":"CD002126","volume":"4","author":"A Lethaby","year":"2005","unstructured":"Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;4:CD002126.","journal-title":"Cochrane Database Syst Rev"},{"key":"1005_CR14","first-page":"CD000400","volume":"1","author":"A Lethaby","year":"2013","unstructured":"Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;1:CD000400.","journal-title":"Cochrane Database Syst Rev"},{"key":"1005_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/1471-0528.14383","volume":"124","author":"X Yao","year":"2017","unstructured":"Yao X, Stewart EA, Laughlin-Tommaso SK, Heien HC, Borah BJ. Medical therapies for heavy menstrual bleeding in women with uterine fibroids: a retrospective analysis of a large commercially insured population in the USA. BJOG. 2017;124:322\u201330.","journal-title":"BJOG."},{"issue":"Suppl 1","key":"1005_CR16","doi-asserted-by":"publisher","first-page":"S-13","DOI":"10.1089\/pop.2017.0151","volume":"21","author":"MM Bonafede","year":"2018","unstructured":"Bonafede MM, Pohlman SK, Miller JD, Thiel E, Troeger KA, Miller CE. Women with newly diagnosed uterine fibroids: treatment patterns and cost comparison for select treatment options. Popul Health Manag. 2018;21(Suppl 1):S-13\u201320.","journal-title":"Popul Health Manag"},{"key":"1005_CR17","volume-title":"The Truven health MarketScan databases for life sciences researchers","author":"L Hansen","year":"2017","unstructured":"Hansen L. The Truven health MarketScan databases for life sciences researchers. 2017. https:\/\/truvenhealth.com\/Portals\/0\/Assets\/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf. Accessed 18 Jul 2019."},{"key":"1005_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8\u201327.","journal-title":"Med Care"},{"key":"1005_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.fertnstert.2007.12.004","volume":"91","author":"DW Lee","year":"2009","unstructured":"Lee DW, Gibson TB, Carls GS, Ozminkowski RJ, Wang S, Stewart EA. Uterine fibroid treatment patterns in a population of insured women. Fertil Steril. 2009;91:566\u201374.","journal-title":"Fertil Steril"},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6874-12-6","volume":"12","author":"A Zimmermann","year":"2012","unstructured":"Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.","journal-title":"BMC Womens Health"},{"key":"1005_CR22","first-page":"1336","volume":"97","author":"ER Becker","year":"2005","unstructured":"Becker ER, Spalding J, DuChane J, Horowitz IR. Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998-2002. J Natl Med Assoc. 2005;97:1336\u201342.","journal-title":"J Natl Med Assoc"},{"key":"1005_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/AOG.0b013e318236fd12","volume":"118","author":"PG Moorman","year":"2011","unstructured":"Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol. 2011;118:1271\u20139.","journal-title":"Obstet Gynecol"},{"key":"1005_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ajog.2005.08.066","volume":"194","author":"CM Farquhar","year":"2006","unstructured":"Farquhar CM, Harvey SA, Yu Y, Sadler L, Stewart AW. A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol. 2006;194:711\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"1005_CR25","volume-title":"State Health Facts. Medicaid Enrollees by Enrollment Group","author":"KFF","year":"2014","unstructured":"KFF. State Health Facts. Medicaid Enrollees by Enrollment Group. 2014. https:\/\/www.kff.org\/medicaid\/state-indicator\/distribution-of-medicaid-enrollees-by-enrollment-group\/?dataView=1&currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed 30 Jan 2020."},{"key":"1005_CR26","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1002\/cncr.30722","volume":"123","author":"CD Hsu","year":"2017","unstructured":"Hsu CD, Wang X, Habif DV Jr, Ma CX, Johnson KJ. Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old. Cancer. 2017;123:3125\u201331.","journal-title":"Cancer."},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jclinane.2017.09.008","volume":"43","author":"HF Xu","year":"2017","unstructured":"Xu HF, White RS, Sastow DL, Andreae MH, Gaber-Baylis LK, Turnbull ZA. Medicaid insurance as primary payer predicts increased mortality after total hip replacement in the state inpatient databases of California, Florida and New York. J Clin Anesth. 2017;43:24\u201332.","journal-title":"J Clin Anesth"},{"key":"1005_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/cncr.29187","volume":"121","author":"AR Rosenberg","year":"2015","unstructured":"Rosenberg AR, Kroon L, Chen L, Li CI, Jones B. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer. 2015;121:1279\u201386.","journal-title":"Cancer."},{"key":"1005_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/rapm-2018-000020","volume":"44","author":"BJ Like","year":"2019","unstructured":"Like BJ, White RS, Tangel V, Sullivan KJ, Arroyo NS, Stambough JB, et al. Medicaid payer status is associated with increased mortality and morbidity after inpatient shoulder arthroplasty: a multistate analysis, 2007\u20132014. Reg Anesth Pain Med. 2019;44:182\u201390.","journal-title":"Reg Anesth Pain Med"},{"key":"1005_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5468\/ogs.2018.61.2.192","volume":"61","author":"GS Sohn","year":"2018","unstructured":"Sohn GS, Cho S, Kim YM, Cho C-H, Kim M-R, Lee SR, et al. Current medical treatment of uterine fibroids. Obstet Gynecol Sci. 2018;61:192\u2013201.","journal-title":"Obstet Gynecol Sci"},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/AOG.0000000000001160","volume":"127","author":"BJ Borah","year":"2016","unstructured":"Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among patients with uterine leiomyomas. Obstet Gynecol. 2016;127:67\u201377.","journal-title":"Obstet Gynecol"},{"key":"1005_CR32","doi-asserted-by":"publisher","first-page":"319.e1","DOI":"10.1016\/j.ajog.2013.07.017","volume":"209","author":"BJ Borah","year":"2013","unstructured":"Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013;209:319.e1\u2013e20.","journal-title":"Am J Obstet Gynecol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01005-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-020-01005-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01005-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:13:59Z","timestamp":1628813639000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-01005-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-01005-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NGB is an employee of Allergan plc and has stock options as an employee of Allergan plc. EB has no disclosures to report. AH is an employee of Allergan plc. AV and LM-S are employees of IBM Watson Health (formerly Truven Health Analytics). PG is an employee of Allergan plc and has stock and stock options as an employee of Allergan plc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}